- Home
- IMAB
IMAB
I-MAB
as 02-21-2025 4:00pm EST
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 79.9M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 263.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $2.00 | Next Earning Date: | 03-13-2025 |
| Revenue: | $569,464 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest I-MAB News
IMAB Breaking Stock News: Dive into IMAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
I-Mab to Participate in Leerink Partners Global Healthcare Conference
GlobeNewswire
18 days ago
I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
PR Newswire
a month ago
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Simply Wall St.
a month ago
US Penny Stocks To Watch In January 2025
Clinical Trials Arena
a month ago
I-Mab pauses CD73 antibody development in pipeline reshuffle
MT Newswires
2 months ago
I-Mab to Prioritize Givastomig as Lead Program; Shares Rise
PR Newswire
2 months ago
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Simply Wall St.
3 months ago
I-Mab Leads Our Spotlight On 3 US Penny Stocks
Compare IMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMAB I-MAB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.